Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists Bruton tyrosine kinase (BTK) is a protein that plays an important role in the signalling, proliferation, migration and survival of B-cells. For this reason, medicines that target BTK — known as BTK…

This interactive learning article, supported by #BeOneMedicines, provides an overview of the available #BTKIs for the treatment of B-cell malignancies to support pharmacists with their use in practice

#cancercare #cancertreatment #pharmacy

Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists Bruton tyrosine kinase (BTK) is a protein that plays an important role in the signalling, proliferation, migration and survival of B-cells. For this reason, medicines that target BTK — known as BTK…

This interactive learning article, supported by #BeOneMedicines, provides an overview of the available #BTKIs for the treatment of B-cell malignancies to support pharmacists with their use in practice

#cancercare #cancertreatment #pharmacy

Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists Bruton tyrosine kinase (BTK) is a protein that plays an important role in the signalling, proliferation, migration and survival of B-cells. For this reason, medicines that target BTK — known as BTK…

This interactive learning article, supported by #BeOneMedicines, provides an overview of the available Bruton tyrosine kinase inhibitors for the treatment of B-cell malignancies to support pharmacists with their use in practice

#BTKIs #cancercare #cancertreatment #pharmacy

BTK Inhibitors Overcome Poor Prognosis of CLL With NOTCH1 Mutations BTKis neutralized the adverse prognostic effect of NOTCH1 mutations in chronic lymphocytic leukemia (CLL), a study found.

Bruton tyrosine kinase inhibitors (#BTKis) appeared to offset the adverse prognostic impact of #NOTCH1 mutations in chronic lymphocytic leukemia (#CLL). Study in European Journal of Haematology.

Read more: https://bit.ly/4gTTqam

#RareDisease #Leukemia #Hematology #Oncology #OncSky #RareSky

Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia | JCO Oncology Practice PURPOSEVenetoclax and Bruton's tyrosine kinase inhibitors (BTKis) are key treatment options for patients with chronic lymphocytic leukemia (CLL) in the frontline setting. This study characterized post...

En el mundo real, la discontinuación temprana es más común en los pacientes que inician un BTKi que los que inician venetoclax con obinutuzumab, con una mayor tasa de hospitalización #venetoclax #BTKIs #CLL ascopubs.org/doi/full/10....